| Name | Zuberitamab |
|---|
| Description | Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma[1]. |
|---|---|
| Related Catalog | |
| In Vivo | Zuberitamab (0.1 mg/kg, intravenous injection, on day 0 and 10, 2 weeks) alone has no or minimal effect on tumor growth, when combined with BR105 results in significant inhibition of tumor growth with good anti-tumor efficacy in IRPα-humanized B-NDG mice tumor xenograft model[1]. |
| References |
| No Any Chemical & Physical Properties |